A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 174, Issue 1, 2014, Pages 86-90

  Cenksoy, Cahit ^a   Cenksoy, Pinar Ozcan ^a   Erdem, Ozlem ^a   Sancak, Banu ^a   Gursoy, Rifat ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

OHSS; Prevention; Relcovaptan; V1a receptor antagonist; VEGF

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; RELCOVAPTAN; SERIC GONADOTROPIN; SODIUM CHLORIDE; VASCULOTROPIN; VASCULOTROPIN A; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS LUTEUM; DRUG INHIBITION; DRUG MEGADOSE; FEMALE; LOW DRUG DOSE; NONHUMAN; ORGAN WEIGHT; OVARY HYPERSTIMULATION; PERITONEAL FLUID; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; WEIGHT GAIN;

OHSS; PREVENTION; RELCOVAPTAN; V1A RECEPTOR ANTAGONIST; VEGF;

ANIMALS; ASCITIC FLUID; CHORIONIC GONADOTROPIN; CORPUS LUTEUM; DISEASE MODELS, ANIMAL; FEMALE; FOLLICULAR ATRESIA; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS, EQUINE; INDOLES; ORGAN SIZE; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; OVULATION INDUCTION; PYRROLIDINES; RATS; RATS, WISTAR; RECEPTORS, VASOPRESSIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASOPRESSINS; WEIGHT GAIN;

EID: 84894243189     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2013.12.001     Document Type: Article

References (33)

1. J.G. Schenker, and D. Weinstein Ovarian hyperstimulation syndrome: a current survey Fertil Steril 30 1978 255 268
2. R. Mathur, C. Kailasam, and J. Jenkins Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome Hum Fertil 10 2007 75 85
3. C.D. Chen, S.U. Chen, and Y.S. Yang Prevention and management of ovarian hyperstimulation syndrome Best Pract Res: Clin Obstet Gynaecol 26 2012 817 827
4. M. Ludwig, O. Bauer, and A. Lopens et al. Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome Hum Reprod 13 1998 30 32
5. R. Mansour, M. Aboulghar, and G. Serour et al. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome Hum Reprod 20 2005 3167 3172
6. G. Nargund, L. Hutchison, and R. Scaramuzzi et al. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles Reprod Biomed Online 14 2007 682 685
7. B. Rizk, M. Aboulghar, and J. Smitz et al. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome Hum Reprod Update 3 1997 255 266
8. H. Tang, T. Hunter, Y. Hu, S.D. Zhai, X. Sheng, and R.J. Hart Cabergoline for preventing ovarian hyperstimulation syndrome Cochrane Database Syst Rev 2 2012 CD008605
9. A. Shaltout, A. Shohyab, and M.A.F.M. Youssef Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study Eur J Obstet Gynecol Reprod Biol 165 2012 254 258
10. A. Tahara, M. Saito, and J. Tsukada et al. Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells Eur J Pharmacol 26 368 1999 89 94
11. A. Morel, A.M. O'Carroll, M.J. Brownstein, and S.J. Lolait Molecular cloning and expression of a rat V1a arginine vasopressin receptor Nature 356 9 1992 523 526
12. M. Birnbaumer, A. Seibold, and S. Gilbert et al. Molecular cloning of the receptor for human antidiuretic hormone Nature 357 28 1992 333 335
13. H.H. Zingg, E. Grazzini, and C. Breton et al. Genomic and non-genomic mechanisms of oxytocin receptor regulation Adv Exp Med Biol 449 1998 287 295
14. A. Tahara, M. Saito, and T. Sugimoto et al. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells Br J Pharmacol 125 1998 1463 1470
15. A. Tahara, Y. Tomura, and K. Wada et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells J Cardiovasc Pharmacol 30 1997 759 766
16. T. Ujioka, K. Matsuura, T. Kawano, and H. Okamura Role of progesterone in capillary permeability in hyperstimulated rats Hum Reprod 12 1997 1629 1634
17. T. Goto, T. Endo, and H. Henmi Gonadotropin-releasing hormone agonist has the ability to induce increased matrix metalloproteinase (MMP)-2 and membrane type 1-MMP expression in corpora lutea, and structural luteolysis in rats J Endocrinol 161 1999 393 402
18. C. Andreu, F. Parborell, S. Vanzulli, H. Chemes, and M. Tesone Regulation of follicular luteinization by a gonadotropin-releasing hormone agonist: relationship between steroidogenesis and apoptosis Mol Reprod Dev 51 1998 287 294
19. R. Sadrkhanloo, C. Hofeditz, and G.F. Erickson Evidence for widespread atresia in the hypophysectomized estrogen-treated rat Endocrinology 120 1987 146 155
20. M.J. Hill, R.J. Chason, M.D. Payson, J.H. Segars, and J.M. Csokmay GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes Reprod BioMed Online 25 2012 284 291
21. X.M. Tong, S.Y. Zhang, and T. Song et al. Effects of gonadotropin- releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome Chin Med J 121 2008 2434 2439
22. S. Kol, and J. Dor Prevention of OHSS: GnRH agonist versus HCG to trigger ovulation Reprod BioMed Online 19 2009 59 60
23. H.G. Al-Inany, M.A. Youssef, and M. Aboulghar et al. Gonadotrophin- releasing hormone antagonists for assisted reproductive technology Cochrane Database Syst Rev 5 2011 CD001750
24. Y. Kitajima, T. Endo, K. Manase, A. Nishikawa, M. Shibuya, and R. Kudo Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats Fertil Steril 81 2004 842 849
25. N. McClure, D.L. Healy, and P.A. Rogers et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome Lancet 344 1994 235 236
26. H. Kobayashi, Y. Okada, T. Asahina, J. Gotoh, and T. Terao The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome Mol Endocrinol 20 1998 363 374
27. A. Delbaere, P.J. Bergmann, C. Gervy-Decoster, M. Camus, V. de Maertelaer, and Y. Englert Prorenin and active renin concentrations in plasma and ascites during severe ovarian hyperstimulation syndrome Hum Reprod 12 1997 236 240
28. Y. Abramov, J.G. Schenker, A. Lewin, S. Friedler, B. Nisman, and V. Barak Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome Hum Reprod 11 1996 1381 1386
29. A. Pellicer, C. Albert, A. Mercader, F. Bonilla-Musoles, J. Remohi, and C. Simon The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1, interleukin-6, and vascular endothelial growth factor Fertil Steril 71 1999 482 489
30. R. Gómez, C. Simón, J. Remohí, and A. Pellicer Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability Biol Reprod 68 2003 2164 2171
31. H.T. Ozcakir, S.G. Giray, M.K. Ozbilgin, U.S. Inceboz, and H. Caglar Effect of angiotensin-converting enzyme-inhibiting therapy on the expression of vascular endothelial growth factor in hyperstimulated rat ovary Fertil Steril 82 2004 1127 1132
32. N. Sugino, S. Kashida, A. Karube-Harada, S. Takiguchi, and H. Kato Expression of vascular endothelial growth factor (VEGF) and its receptors in human endometrium throughout the menstrual cycle and in early pregnancy Reproduction 123 2002 379 387
33. I. Miwa, H. Tamura, A. Takasaki, Y. Yamagata, K. Shimamura, and N. Sugino Pathophysiologic features of "thin" endometrium Fertil Steril 91 2009 998 1004